IL32 and neoplasm: Deficiency of cross-presenting DC (in Batf3–/– mice) or CD8+ T cells abrogated the therapeutic efficacy of IL-32 in mice, suggesting that the IL-32 effector mechanisms are dependent on cDC1 priming of tumor-specific CD8+ T cells.